A recent study compared the effectiveness of obeticholic acid and fibrates as second-line treatments for Primary Biliary Cholangitis (PBC) patients who do not respond adequately to the initial therapy, ursodeoxycholic acid (UDCA).
This is important because about 40% of PBC patients have a suboptimal response to UDCA, creating a need for alternative treatment options.
The study highlights the significance of finding effective therapies to improve patient outcomes and manage disease progression.
The research aims to clarify which second-line therapy might be more beneficial for patients with incomplete response to UDCA.
By evaluating obeticholic acid and fibrates, the study provides valuable insights to help clinicians select the best treatment approach for these patients, enhancing PBC management beyond standard care Abreu (2025).
Clinical Trials
This is a list of upcoming or ongoing clinical trials that are actively recruiting and have been listed or updated in the last two weeks:
